Tara D. Sutton

The State Rested

On April 11, 2023, Minnesota finished presenting eleven witnesses in the first state trial against JUUL and Altria. Tara D. Sutton had returned to a tobacco courtroom twenty-five years after serving on the trial team that confronted the cigarette industry in 1998.

The two trials addressed different products and different routes to young users. The 1998 defendants sold cigarettes. Minnesota’s 2023 case examined flavors, nicotine delivery, product design, social media, and lifestyle marketing surrounding an electronic device. Sutton moved from trial-team responsibility in the first matter to lead trial counsel in the second.

Four Months in 1998

Minnesota retained Robins Kaplan and Michael Ciresi as special counsel in 1994. The State and Blue Cross and Blue Shield of Minnesota sought recovery for healthcare costs while challenging cigarette marketing, concealment, and industry conduct. Trial began in January 1998.

Sutton helped carry approximately four months of witness and exhibit presentation. After both sides rested, the companies agreed to pay the State approximately $6.1 billion over twenty-five years, with the combined State and Blue Cross resolution exceeding $6.6 billion.

The settlement did more than establish a payment schedule. It imposed advertising and marketing restrictions and opened millions of internal industry documents to the public. The money addressed past public spending; the restrictions governed future promotion; and the document archive gave researchers, regulators, journalists, and later litigants access to the industry’s own records.

That assignment placed Sutton inside a state case that translated public-health injury into admissible proof, long-term payment obligations, continuing marketing rules, and public corporate documents. The same combination of trial evidence and forward-looking relief returned when Minnesota confronted youth vaping.

Three Weeks in 2023

Minnesota sued JUUL in December 2019 and later added Altria, pursuing consumer-protection, negligence, public-nuisance, unjust-enrichment, and conspiracy claims. Sutton’s team developed evidence concerning youth-focused product design, flavors, nicotine delivery, social-media promotion, Altria’s investment and distribution work, and the public-health costs of adolescent addiction.

Trial began on March 28, 2023. Attorney General Keith Ellison and Sutton divided the opening statement. Over the next two weeks, the State used eleven witnesses to address JUUL’s launch campaign, youth appeal, flavors, internal communications, Altria’s involvement, and the costs of youth vaping. Minnesota rested on April 11.

Six days later, the parties announced a binding settlement. The May 17 consent judgment required JUUL and Altria to pay $60.5 million over eight years and imposed enforceable disclosure, retailer-compliance, youth-marketing, social-media, flavor, sponsorship, sampling, online-sales, and in-store restrictions.

What the Consent Judgment Kept Doing

The judgment frontloaded its payments: $22.75 million was due within thirty days and another $12.75 million by March 2024, placing nearly sixty percent of the $60.5 million with Minnesota during the first year. Minnesota directed the net public recovery toward preventing youth smoking, vaping, and nicotine addiction. Separately from the State’s $60.5 million recovery, Minnesota estimated $8.6 million in litigation costs and approximately $8.9 million in outside-counsel fees.

The nonmonetary terms followed the paths by which Minnesota alleged the product reached young consumers. JUUL accepted restrictions on marketing to children and young adults, models under thirty-five, apparel and entertainment advertising, social media, outdoor promotion, event sponsorship, samples, flavored products, online sales, and in-store practices. The judgment also required accurate nicotine disclosure and a retailer-compliance program built around age verification.

JUUL and Altria had to place Minnesota litigation materials in public document repositories, continuing a remedy central to the 1998 tobacco case. Those records remain available after the payments are distributed, allowing later corporate statements and regulatory questions to be tested against the companies’ own materials.

The settlement joined early prevention funding, public access to documents, sales and marketing restrictions tied to the alleged route to young users, and a court judgment capable of enforcement. Its operation continued after the courtroom emptied.

A Sovereign Table

Sutton’s opioid work required a different governmental structure. She represented twenty-eight Tribal Nations in litigation alleging that opioid manufacturers distorted the risks of long-term use and that distributors failed to identify and stop suspicious orders. The Tribes sought resources for treatment, healthcare, child welfare, public safety, family services, and recovery systems within their communities.

Each Tribe possessed its own governmental authority, public-health responsibilities, and claimed loss. Sutton participated in negotiations that created direct settlement paths for Tribes rather than routing their claims through state or county allocations or treating them as subdivisions of another sovereign.

Johnson & Johnson agreed to pay $150 million over two years. McKesson, Cardinal Health, and AmerisourceBergen entered a $515 million distributor agreement with a separately allocated Cherokee component. Both agreements opened participation to all 574 federally recognized Tribes, including governments that had not filed suit.

Sutton helped structure participation, release, allocation, and payment terms capable of working across governments of different sizes. The agreements directed abatement resources to the Tribes themselves while preserving each government’s authority to select culturally appropriate treatment, prevention, family services, recovery systems, and traditional healing practices. Common settlement terms supplied scale; each Nation retained judgment over the work needed in its own community.

The First Mirapex Bellwether

Mirapex moved Sutton from public-entity claims to the private consequences of a pharmaceutical warning. Pramipexole is prescribed for Parkinson’s disease and restless legs syndrome. Patients alleged that it could trigger or intensify compulsive behavior, including pathological gambling, and that the manufacturers failed to provide an adequate warning before label changes.

Federal courts centralized cases sharing questions about scientific causation, warning history, labeling, and compulsive behavior in the District of Minnesota. The common record could address what the companies knew and when the label changed. Each plaintiff still needed an individual record: prescription dates, physician decisions, onset and course of behavior, alternative causes, reliance under governing law, and what a different warning would have changed.

Sutton served as lead trial counsel in Charbonneau v. Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer, Inc., the first Mirapex bellwether. On July 30, 2008, the jury awarded $8,279,300, including $7.8 million in punitive damages, on the failure-to-warn claim.

The verdict gave the broader docket a public measure of the warning evidence, causation case, claimed injury, and jury response. Sutton then applied the common record without treating individual patients as interchangeable. Successive trial preparation helped resolve more than 280 Mirapex cases handled by her firm, with claimant-specific medical histories and losses still governing each file.

She also led expert-admissibility work in proceedings involving Mirapex, Chantix, Abilify, and JUUL. That work required medical literature, product history, scientific methods, and individual evidence to support reliable general- and specific-causation testimony before the court and jury.

A Matrix for Failed Hip Implants

The Stryker Rejuvenate and ABG II litigation began at a modular neck-stem junction. The hip systems used separate components intended to give surgeons flexibility in fitting an implant. Stryker recalled the products in 2012 because fretting and corrosion at the junction could cause adverse local tissue reactions. Plaintiffs alleged pain, swelling, metal debris, metallosis, necrosis, bone loss, and revision surgery.

New Jersey centralized the state cases for coordinated management. Sutton represented claimants there, including two plaintiffs whose matters proceeded through court-ordered bellwether mediation. Judge Brian Martinotti appointed her as one of four plaintiffs’ lawyers who negotiated a broader program before retired federal Magistrate Judge Diane Welsh; federal multidistrict-litigation counsel later joined the agreement.

The 2014 program established a $300,000 base award per failed implant, with additional compensation keyed to documented complications and economic loss, including infection, dislocation, nerve injury, lost wages, and repeat surgery. It also created a recovery path for patients who needed revision but were medically unable to undergo the operation. The program carried no overall cap and was expected to provide more than $1 billion in compensation.

Approximately ninety-five percent of registered eligible patients enrolled. A 2016 agreement extended the same architecture to additional patients revised by a later date. The common matrix gave the program consistency, while medical records, surgeries, complications, limitations, and economic consequences shaped each claimant’s award.

Fifteen Witnesses and an Aerosol Duster

Sutton co-led the trial team in McDougall v. CRC Industries, Inc., a product-liability case arising from a fatal 2019 collision involving inhalation of difluoroethane from an aerosol duster. The seven-day trial presented fifteen witnesses on warnings, foreseeable misuse, causation, and damages.

In April 2024, the jury returned a $7.75 million verdict against the manufacturer—the first known plaintiff verdict reached at trial against an aerosol-duster manufacturer. The result extended Sutton’s warning and causation work to a consumer product with a different use, risk record, and chain of proof.

The Science Gate

Sutton chairs Robins Kaplan’s National Mass Tort Group and serves on the Plaintiffs’ Executive Committee in Depo-Provera MDL No. 3140. She served on the firm’s Executive Board from 2015 through 2024 and has held long-term leadership roles with Public Justice, including its presidency.

Her court-appointed leadership record extends across several national mass-tort proceedings, where she has served in committee, settlement-counsel, lead-counsel, and liaison-counsel roles in addition to her current Depo-Provera appointment.

In the Depo-Provera MDL, Sutton helped negotiate an opportunity for eligible plaintiffs to resolve claims. Her work continues across expert development, preemption briefing, claimant documentation, and the administration of paths serving both participating plaintiffs and claims that continue in litigation.

She earned her undergraduate degree with high honors and her law degree with honors from the University of Iowa, graduating from law school in 1992. Her practice has required her to turn studies, labels, adverse-event information, product design, marketing, medical histories, and government costs into proof that survives the rules governing each forum.

The form of that proof changes with the client and remedy. Minnesota’s JUUL case ended in an enforceable public-health judgment; Tribal opioid claims required sovereign allocations; Stryker claims entered a compensation matrix; and Mirapex proceeded through a jury verdict and later claimant resolutions. Sutton’s work has carried separate records from trial evidence through the distinct judgment, allocation formula, agreement, or claims process that made relief usable.